[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketinside...] --------------------------------------------------------------- [Why is Russia reopening dormant copper mines?]( [Here's where to look]([aff_i?offer_...] --------------------------------------------------------------- October 18, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [YIKES! 220 Pounds of Graphite in Each EV Battery?]( [e225bc59-31e...](Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution ñ until now. [See Why Savvy Investors Could Benefit From Huge Pent-Up Demand]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [AVEO Pharma, AVEO]( Recent Analyst Action: Andrew Berens, analyst at SVB Securities, reiterates coverage on [AVEO Pharma (AVEO)](in the Healthcare sector with a Buy rating (6 days ago). - Recent Price: $14.74 - Average Analyst Price Target: $15.67 (6.31%) - Market Cap: $362.76M [TipRanks.com]( also reports that [AVEO Pharma](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.67. The target pricing ranges from a high forecast of $17.00 down to a low forecast of $15.00. [AVEO Pharma (AVEO)](’s last closing price was $14.74 which would put the average price target at $15.67. Here are 3rd party ratings for [AVEO](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 23% (57 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [America's No. 1 Favorite Investment (Is Robbing You Blind)]( [e7c96773-eb3...](“$20 trillion in U.S. household wealth is invested in a total scam.” Those are the words of retired Lt. Col. Michael J. Carr, U.S. Air Force, CMT, CFTe. I didn’t want to believe it at first … but once he showed me the evidence, I couldn’t dispute it. [Every American with retirement savings should watch this video.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Service Properties, SVC]( Recent Analyst Action: Dori Kesten, analyst at Wells Fargo, reiterates coverage on [Service Properties (SVC)](in the Financial sector with a Sell rating and a price target of $6.75 (1 month ago). - Recent Price: $7.93 - Average Analyst Price Target: $6.75 (-14.88%) - Market Cap: $1.28B [TipRanks.com]( also reports that [Service Properties](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Sell rating with an average price target is $6.75. The target pricing ranges from a high forecast of $6.75 down to a low forecast of $6.75. [Service Properties (SVC)](’s last closing price was $7.93 which would put the average price target at $6.75. Here are 3rd party ratings for [SVC](: - TipRanks.com: Moderate Sell - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 36% (90 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [Sonder Holdings, SOND]( Recent Analyst Action: Nicholas Jones, analyst at JMP Securities, reiterates coverage on [Sonder Holdings (SOND)](in the Services sector with a Buy rating and a price target of $3.5 (2 months ago). - Recent Price: $2.185 - Average Analyst Price Target: $3.50 (60.18%) - Market Cap: $476.23M [TipRanks.com]( also reports that [Sonder Holdings](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $3.50. The target pricing ranges from a high forecast of $3.50 down to a low forecast of $3.50. [Sonder Holdings (SOND)](’s last closing price was $2.185 which would put the average price target at $3.50. Here are 3rd party ratings for [SOND](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Bottom 47% (132 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Screen+Shot+...]( [Click here]( for the name of the one ticker you need to protect yourself.[5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [BeiGene, BGNE]( Recent Analyst Action: Michael Schmidt, analyst at Guggenheim, reiterates coverage on [BeiGene (BGNE)](in the Healthcare sector with a Buy rating and a price target of $205.00 (5 days ago). - Recent Price: $169.39 - Average Analyst Price Target: $248.27 (46.57%) - Market Cap: $34.15B [TipRanks.com]( also reports that [BeiGene](currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $248.27. The target pricing ranges from a high forecast of $296.00 down to a low forecast of $200.00. [BeiGene (BGNE)](’s last closing price was $169.39 which would put the average price target at $248.27. Here are 3rd party ratings for [BGNE](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 23% (57 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [Viking Therapeutics, VKTX]( Recent Analyst Action: Thomas Smith, analyst at SVB Securities, reiterates coverage on [Viking Therapeutics (VKTX)](in the Healthcare sector with a Buy rating and a price target of $12.00 (1 week ago). - Recent Price: $4.08 - Average Analyst Price Target: $15.75 (286.03%) - Market Cap: $288.35M [TipRanks.com]( also reports that [Viking Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.75. The target pricing ranges from a high forecast of $21.00 down to a low forecast of $10.00. [Viking Therapeutics (VKTX)](’s last closing price was $4.08 which would put the average price target at $15.75. Here are 3rd party ratings for [VKTX](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 23% (57 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [The 800-lb Chinese Gorilla]( [5439d433-d80...](China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now. [Find Out Where This Copper Hotspot Is and How You Can Benefit]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Kymera Therapeutics, KYMR]( Recent Analyst Action: Zhiqiang Shu, analyst at Berenberg Bank, reiterates coverage on [Kymera Therapeutics (KYMR)](in the Healthcare sector with a Buy rating and a price target of $68.00 (1 day ago). - Recent Price: $26.055 - Average Analyst Price Target: $56.50 (116.85%) - Market Cap: $1.31B [TipRanks.com]( also reports that [Kymera Therapeutics](currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $56.50. The target pricing ranges from a high forecast of $93.00 down to a low forecast of $37.00. [Kymera Therapeutics (KYMR)](’s last closing price was $26.055 which would put the average price target at $56.50. Here are 3rd party ratings for [KYMR](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 23% (57 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [Verrica Pharmaceuticals, VRCA]( Recent Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on [Verrica Pharmaceuticals (VRCA)](in the Healthcare sector with a Buy rating and a price target of $11.00 (2 months ago). - Recent Price: $3.14 - Average Analyst Price Target: $7.50 (138.85%) - Market Cap: $120.41M [TipRanks.com]( also reports that [Verrica Pharmaceuticals](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.50. The target pricing ranges from a high forecast of $11.00 down to a low forecast of $4.00. [Verrica Pharmaceuticals (VRCA)](’s last closing price was $3.14 which would put the average price target at $7.50. Here are 3rd party ratings for [VRCA](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 31% (77 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- ["We need batteries. Literally everywhere."]( [b7d51c88-c8f...](Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." [Read about this company's once-in-a-lifetime graphite opportunity -- before Wall Street]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, The Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software